Search Results - "C. Isaacs"

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study by Lynce, F., Barac, A., Geng, X., Dang, C., Yu, A. F., Smith, K. L., Gallagher, C., Pohlmann, P. R., Nunes, R., Herbolsheimer, P., Warren, R., Srichai, M. B., Hofmeyer, M., Cunningham, A., Timothee, P., Asch, F. M., Shajahan-Haq, A., Tan, M. T., Isaacs, C., Swain, S. M.

“…Purpose HER2-targeted therapies have substantially improved the outcome of patients with breast cancer, however, they can be associated with cardiac toxicity…”
Get full text

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy by Du, L., Yau, C., Brown-Swigart, L., Gould, R., Krings, G., Hirst, G.L., Bedrosian, I., Layman, R.M., Carter, J.M., Klein, M., Venters, S., Shad, S., van der Noordaa, M., Chien, A.J., Haddad, T., Isaacs, C., Pusztai, L., Albain, K., Nanda, R., Tripathy, D., Liu, M.C., Boughey, J., Schwab, R., Hylton, N., DeMichele, A., Perlmutter, J., Yee, D., Berry, D., van't Veer, L., Valero, V., Esserman, L.J., Symmans, W.F.

“…We proposed that a test for sensitivity to the adjuvant endocrine therapy component of treatment for patients with stage II-III breast cancer (SET2,3) should…”
Get full text

Anthropometric and Hormonal Risk Factors for Male Breast Cancer: Male Breast Cancer Pooling Project Results by BRINTON, Louise A, COOK, Michael B, GAZIANO, J. Michael, GKIOKAS, Georgios, GUENEL, Pascal, HENDERSON, Brian E, HOLLENBECK, Albert, HSING, Ann W, KOLONEL, Laurence N, ISAACS, Claudine, LUBIN, Jay H, MICHELS, Karin B, MCCORMACK, Valerie, NEGRI, Eva, PARISI, Dominick, PETRIDOU, Eleni Th, PIKE, Malcolm C, RIBOLI, Elio, SESSO, Howard D, SNYDER, Kirk, SWERDLOW, Anthony J, TRICHOPOULOS, Dimitrios, URSIN, Giske, JOHNSON, Kenneth C, VAN DEN BRANDT, Piet A, VAN DEN EEDEN, Stephen K, WEIDERPASS, Elisabete, WILLETT, Walter C, EWERTZ, Marianne, THOMAS, David B, OLSSON, Håkan, CASAGRANDE, John T, COOKE, Rosie, FALK, Roni T, GAPSTUR, Susan M, GAUDET, Mia M

“…The etiology of male breast cancer is poorly understood, partly because of its relative rarity. Although genetic factors are involved, less is known regarding…”
Get full text

P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy by Bardia, A., Pusztai, L., Albain, K., Kalinsky, K., Hershman, D., Barlow, W., Tokunaga, E., Ciruelos, E.M., Loirat, D., Isaacs, C., Testa, L., Dry, H., Kozarski, R., Maxwell, M., Harbeck, N., Sharma, P.

Get full text

Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer by Mainor, C. B., Isaacs, C.

“…Purpose of Review We review the management for unaffected BRCA1/2 mutation carriers and the local management of early-stage breast cancer. Recent Findings For…”
Get full text

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809 by Shapiro, C.L, Halabi, S, Hars, V, Archer, L, Weckstein, D, Kirshner, J, Sikov, W, Winer, E, Burstein, H.J, Hudis, C, Isaacs, C, Schilsky, R, Paskett, E

“…Abstract Background Chemotherapy-induced ovarian failure (CIOF) is a frequent side-effect of adjuvant chemotherapy that results in rapid bone loss. We…”
Get full text

Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers by Eisen, Andrea, Lubinski, Jan, Gronwald, Jacek, Moller, Pal, Lynch, Henry T., Klijn, Jan, Kim-Sing, Charmaine, Neuhausen, Susan L., Gilbert, Lucy, Ghadirian, Parviz, Manoukian, Siranoush, Rennert, Gad, Friedman, Eitan, Isaacs, Claudine, Rosen, Eliot, Rosen, Barry, Daly, Mary, Sun, Ping, Narod, Steven A.

“…Background Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this…”
Get full text

Evaluation of WLBU2 Peptide and 3-O-Octyl-sn-Glycerol Lipid as Active Ingredients for a Topical Microbicide Formulation Targeting Chlamydia trachomatis by SKINNER, M. C, KISELEV, A. O, ISAACS, C. E, MIETZNER, T. A, MONTELARO, R. C, LAMPE, M. F

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Protracted rainfall decreases temperature within leatherback turtle ( Dermochelys coriacea) clutches in Grenada, West Indies: Ecological implications for a species displaying temperature dependent sex determination by Houghton, J.D.R., Myers, A.E., Lloyd, C., King, R.S., Isaacs, C., Hays, G.C.

“…Protracted or intense rainfall may affect the reproductive success of reptilian species on a number of levels ranging from the availability of prey, the…”
Get full text

BRCA1 in hormonal carcinogenesis: basic and clinical research by Rosen, E M, Fan, S, Isaacs, C

“…The breast and ovarian cancer susceptibility gene-1 (BRCA1) located on chromosome 17q21 encodes a tumor suppressor gene that functions, in part, as a caretaker…”
Get full text

Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study by Tsai, H.-T., Isaacs, C., Fu, A. Z., Warren, J. L., Freedman, A. N., Barac, A., Huang, C.-Y., Potosky, A. L.

“…Randomized controlled trials have reported a 4–5 times increased risk of heart failure (HF) in breast cancer patients receiving trastuzumab (Herceptin ® )…”
Get full text

Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers by Rebbeck, Timothy R., Levin, Albert M., Eisen, Andrea, Snyder, Carrie, Watson, Patrice, Cannon-Albright, Lisa, Isaacs, Claudine, Olopade, Olofunmilayo, Garber, Judy E., Godwin, Andrew K., Daly, Mary B., Narod, Steven A., Neuhausen, Susan L., Lynch, Henry T., Weber, Barbara L.

“…BACKGROUND: The availability of genetic testing for inherited mutations in the BRCA1 gene provides potentially valuable information to women at high risk of…”
Get full text

Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination by Andre, E., Isaacs, C., Affolabi, D., Alagna, R., Brockmann, D., de Jong, B. C., Cambau, E., Churchyard, G., Cohen, T., Delmee, M., Delvenne, J-C., Farhat, M., Habib, A., Holme, P., Keshavjee, S., Khan, A., Lightfoot, P., Moore, D., Moreno, Y., Mundade, Y., Pai, M., Patel, S., Nyaruhirira, A. U., Rocha, L. E. C., Takle, J., Trébucq, A., Creswell, J., Boehme, C.

“…In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is increasing dramatically, including in resource-limited…”
Get full text

Alcohol and risk of breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple tumor characteristics by Falk, Roni T, Maas, Paige, Schairer, Catherine, Chatterjee, Nilanjan, Mabie, Jerome E, Cunningham, Christopher, Buys, Saundra S, Isaacs, Claudine, Ziegler, Regina G

“…Alcohol consumption is an established risk factor for breast cancer. Whether associations vary by specific tumor characteristics independent of other…”
Get full text

Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers by Schrader, K A, Masciari, S, Boyd, N, Salamanca, C, Senz, J, Saunders, D N, Yorida, E, Maines-Bandiera, S, Kaurah, P, Tung, N, Robson, M E, Ryan, P D, Olopade, O I, Domchek, S M, Ford, J, Isaacs, C, Brown, P, Balmana, J, Razzak, A R, Miron, P, Coffey, K, Terry, M B, John, E M, Andrulis, I L, Knight, J A, O'Malley, F P, Daly, M, Bender, P, Moore, R, Southey, M C, Hopper, J L, Garber, J E, Huntsman, D G

“…Germline mutations in CDH1 are associated with hereditary diffuse gastric cancer; lobular breast cancer also occurs excessively in families with such…”
Get more information

Infertility coverage is good business by Isaacs, Joseph C., M.S.P.H

“…Tens of thousands of people struggling with infertility and lacking applicable insurance coverage continue to find needed care beyond their affordable reach…”
Get full text

A structure–reactivity relationship driven approach to the identification of a color test protocol for the presumptive indication of synthetic cannabimimetic drugs of abuse by Isaacs, Richard C.A

“…Highlights • Synthetic cannabimimetic drugs do not respond to the Duquenois–Levine color test. • The lack of response was rationalized using structure and…”
Get full text

Breast-feeding and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers by Jernström, H., Lubinski, J., Lynch, H. T., Ghadirian, P., Neuhausen, S., Isaacs, C., Weber, B. L., Horsman, D., Rosen, B., Foulkes, W. D., Friedman, E., Gershoni-Baruch, R., Ainsworth, P., Daly, M., Garber, J., Olsson, H., Sun, P., Narod, S. A.

“…Background: Several studies have reported that the risk of breast cancer decreases with increasing duration of breast-feeding. Whether breast-feeding is…”
Get full text

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors by Stearns, V., Isaacs, C., Rowland, J., Crawford, J., Ellis, M. J., Kramer, R., Lawrence, W., Hanfelt, J.J., Hayes, D.F.

“…Background: Many breast cancer survivors suffer debilitating hot flashes. Estrogen, the drug of choice in perimenopausal women, is generally not recommenced to…”
Get full text

Analytical challenges in the confirmative identification of dipyrone as an adulterant in illicit drug samples by Isaacs, Richard C.A, Harper, Michaela M, Miller, Emily C

“…Highlights • Dipyrone undergoes thermal and/or hydrolytic decomposition during GC and GC–MS analysis. • There are two possible decomposition products:…”
Get full text